Gilead’s HIV treatment trials involving an investigational integrase strand inhibitor (GS-1720) and an investigational capsid inhibitor (GS-4182) have been put on clinical hold by the Food and Drug ...

Nadunolimab is a fully humanized Fc-enhanced IgG1 monoclonal antibody targeting interleukin 1 receptor accessory protein.

Granuloma annulare is a benign inflammatory skin condition that typically presents with annular plaques or grouped papules with central clearing. The ...

Eliminating fluoridation estimated to increase dental caries prevalence, total number of decayed teeth, and up costs.

HealthDay News — Rates of colorectal cancer detection through colonoscopy screening are similar for adults aged 45 to 49 years and 50 to 54 years, according to a research letter published online June ...

HealthDay News — Adherence to a Mediterranean diet (MD) provides symptom relief in adults with diarrhea-predominant irritable bowel syndrome (IBS-D) or mixed bowel pattern IBS (IBS-M) according to a ...

The ACIP is a federal advisory committee composed of medical and public health experts who make recommendations on the use of vaccines for adults and children in the US.

“Pediatric skin care regimens on TikTok provide little benefit and may expose children to harm,” the authors write. “These videos reflect and may amplify unattainable beauty standards and age bias ...

The Food and Drug Administration (FDA) has approved Xifyrm ™ (meloxicam injection) for use in adults for the management of moderate to severe pain, alone or in combination with non-NSAID ...

Lurbinectedin plus atezolizumab significantly reduced the risk of disease progression or death by 46% compared with atezolizumab alone.

Zoliflodacin is an oral, single dose spiropyrimidinetrione that has activity against multidrug-resistant strains of Neisseria gonorrhoeae.

The Food and Drug Administration (FDA) has approved Enflonsia ™ (clesrovimab-cfor) for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in neonates and infants who ...